2 weeks Ago By ABMN Staff
Norges Bank purchased a new position in shares of Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX – Free Report ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 91,770 shares of the biopharmaceutical company’s stock, valued at approximately $1,915,000.
Norges Bank owned about 0.08% of Catalyst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Several other institutional investors and hedge funds have also recently bought and sold shares of CPRX.
Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $27,000. Farther Finance Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter.
Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. KBC Group NV boosted its stake in Catalyst Pharmaceuticals by 48.
8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc.
acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $134,000. Institutional investors and hedge funds own 79.22% of the company’s stock.
Analysts Set New Price Targets Several equities research analysts recently weighed in on CPRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th.
Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.
00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Bank of America reissued a “buy” rating and issued a $30.
00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th.
Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.29.
Catalyst Pharmaceuticals Stock Up 2.8 % CPRX opened at $22.05 on Friday.
The firm has a market cap of $2.68 billion, a PE ratio of 18.69, a P/E/G ratio of 3.
31 and a beta of 0.79. The business has a fifty day simple moving average of $22.
63 and a 200-day simple moving average of $22.00. Catalyst Pharmaceuticals, Inc.
has a fifty-two week low of $14.47 and a fifty-two week high of $26.16.
Insider Activity In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.
50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72.
The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website .
Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.
36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57.
This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here .
11.00% of the stock is currently owned by company insiders. Catalyst Pharmaceuticals Company Profile ( Free Report ) Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. See Also Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
